dehydroepiandrosterone; prasterone (DHEA, Aslera, Intrarosa)

From Aaushi
Jump to navigation Jump to search

Introduction

In females:

30-50 mg/day is produced by zona fasciculata & zona reticularis of the adrenal cortex.

Quantitatively, the major secretory product of the adrenal gland. Adrenal production is regulated by ACTH. No known receptors for DHEA. Activity appears to be solely due to activity of its 2 metabolites, testosterone & estrone.

Concentrated in specific areas of the paleocortex in humans.

Pharmacology

prasterone. Tradenames: Aslera, Intrarosa

Indications

Dosage

50-200 mg PO QD

Tabs: 200 mg (Aslera)

Once a day vaginal insert for dyspareunia (Intrarosa)

Pharmacokinetics

Monitor

liver function tests[4]

Adverse effects

Drug interactions

Mechanism of action

More general terms

More specific terms

Additional terms

References

  1. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 243
  2. Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
  3. Prescriber's Letter 7(12):70 2000
  4. 4.0 4.1 Prescriber's Letter 8(8):48 2001
  5. 5.0 5.1 Solomon D. In: Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
  6. 6.0 6.1 6.2 6.3 6.4 Prescriber's Letter 12(1): 2005 DHEA and Abdominal Obesity Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210115&pb=PRL (subscription needed) http://www.prescribersletter.com
  7. 7.0 7.1 7.2 Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA. 2004 Nov 10;292(18):2243-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15536111
  8. 8.0 8.1 8.2 Olech E & Merril JT, DHEA supplementation: The claims in perspective, Cleveland Clinic Journal of Medicine 72(11): 965, 2005
  9. 9.0 9.1 Nair KS et al DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006 Oct 19; 355:1647-59 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17050889
    Stewart PM. Aging and fountain-of-youth hormones. N Engl J Med 2006 Oct 19; 355:1724-6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17050897
  10. 10.0 10.1 Prescriber's Letter 13(12): 2006 Anti-aging effects of DHEA Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=221208&pb=PRL (subscription needed) http://www.prescribersletter.com
  11. Igwebuike A et al, Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women. J Clin Endocrinol 2008, 93:534 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18029465
  12. 12.0 12.1 Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
  13. 13.0 13.1 Brooks M FDA OKs Prasterone for Dyspareunia in Postmenopausal Women. Medscape. Nov 17, 2016 http://www.medscape.com/viewarticle/872022
    FDA News Release. November 17, 2016 FDA approves Intrarosa for postmenopausal women experiencing pain during sex. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm529641.htm

Database